The adverse effects of pharmaceuticals on the central or peripheral nervous systems
are poorly predicted by the current in vitro and in vivo preclinical studies performed during
research and development process. Increasing the predictivity of the preclinical toolbox is a
clear need, and would benefit to human volunteers/patients (safer drugs) and
pharmaceutical industry (reduced attrition). The NeuroDeRisk Consortium consists of 18
academic, pharmaceutical industry and small and medium enterprise partners within the
Innovative Medicines Initiative project (2019-2022). University of Belgrade – Faculty of
Pharmacy is the partner that leads the work package devoted to preclinical prediction of
mood and cognitive adverse effects. The other two groups of challenging adverse effects
tackled by the project are seizures and peripheral neuropathies. By employing a plethora of
experimental techniques and numerous pharmaceuticals previously connected with each of
major adverse effects examined, the project looks for innovative tools, assays and protocols,
which cover in silico, in vitro, in vivo and ex vivo approaches. Besides widening the
knowledge on many widely used pharmaceuticals, the major goal of the project is to develop
an integrated platform for better risk-assessment in exploratory and regulatory studies in
the future.Postojeće in vitro i in vivo prekliničke studije koje se sprovode tokom procesa
istraživanja i razvoja teško mogu predvideti neželjene efekte farmaceutika na centralni i
periferni nervni sistem. Postoji jasna potreba za povećanjem prediktivnosti prekliničkih
oruđa, što bi bilo korisno za humane volontere/pacijente (bezbedniji lekovi) i farmaceutsku
industriju (smanjena stopa neuspeha). NeuroDeRisk konzorcijum se sastoji od 18
akademskih institucija, kompanija farmaceutske industrije i malih i srednjih preduzeća u
okviru projekta Inicijative za inovativne lekove (2019-2022). Univerzitet u Beogradu –
Farmaceutski fakultet jeste partner koji predvodi radni parket posvećen prekliničkom
predviđanju neželjenih efekata na raspoloženje i kogniciju. Druge dve grupe izazovnih
neželjenih efekata koje projekat obrađuje jesu konvulzivni napadi i periferne neuropatije.
Korišćenjem mnoštva eksperimentalnih tehnika i brojnih farmaceutika koji su prethodno
povezani sa svakim od ispitivanih velikih neželjenih efekata, projekat traga za inovativnim
oruđima, esejima i protokolima, koji pokrivaju in silico, in vitro, in vivo i ex vivo pristupe.
Mimo širenja znanja o brojnim široko korišćenim farmaceuticima, glavni cilj projekta jeste
razvoj integrisane platforme za bolju procenu rizika u budućim eksploratornim i
regulatornim studijama.VIII Kongres farmaceuta Srbije sa međunarodnim učešćem, 12-15.10.2022. Beogra
